Prostate cancer (PC) is more common among and kills more African American (AA) males than men of other races and ethnicities, including European Americans (EA). 1,2 This disparity has been linked in part to socioeconomic factors, limited access to healthcare, and individual genetic susceptibilities.
To determine whether genetic/biologic factors have an impact on ethnic inequalities in PC pathogenesis and disease progression, an investigation was performed on the ethnicity-specific expression of prostate cancer (PC)-associated biomarkers.
The risk of one or more unfavorable clinicopathologic outcomes in AA men can be predicted using a set of biomarkers that demonstrate ethnic reliance. These findings demonstrate that there are variations in PC biology and pathogenesis between AAmen and EAmen that have an impact on applicability for both diagnostics and therapies. For use in PC diagnosis and treatment, further testing is necessary. Clinicians will be able to more precisely risk stratify these patients for recommended treatments that will enhance disease control and ultimately lessen the disparities in outcomes in this patient population by being able to identify a subset of AA males who have severe illnesses.
Learn more about PC here:
https://brainly.com/question/26029834
#SPJ4
